These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 28957950)

  • 1. Management of Preinvasive Lesions.
    Patrono MG; Corzo C; Iniesta M; Ramirez PT
    Clin Obstet Gynecol; 2017 Dec; 60(4):771-779. PubMed ID: 28957950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical outcomes in patients with isolated serous tubal intraepithelial carcinoma (STIC): A comprehensive review.
    Patrono MG; Iniesta MD; Malpica A; Lu KH; Fernandez RO; Salvo G; Ramirez PT
    Gynecol Oncol; 2015 Dec; 139(3):568-72. PubMed ID: 26407480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
    van den Berg CB; Dasgupta S; Ewing-Graham PC; Bart J; Bulten J; Gaarenstroom KN; de Hullu JA; Mom CH; Mourits MJE; Steenbeek MP; van Marion R; van Beekhuizen HJ
    Gynecol Oncol; 2024 Aug; 187():113-119. PubMed ID: 38759517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting: analysis of a case series.
    Morrison JC; Blanco LZ; Vang R; Ronnett BM
    Am J Surg Pathol; 2015 Apr; 39(4):442-53. PubMed ID: 25517955
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of risk-reducing salpingo-oophorectomy in BRCA1-2 variants and clinical outcomes of follow-up in patients with isolated serous tubal intraepithelial carcinoma (STIC).
    Saccardi C; Zovato S; Spagnol G; Bonaldo G; Marchetti M; Alessandrini L; Tognazzo S; Guerriero A; Vitagliano A; Laganà AS; Noventa M
    Gynecol Oncol; 2021 Nov; 163(2):364-370. PubMed ID: 34465478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence for a dualistic model of high-grade serous carcinoma: BRCA mutation status, histology, and tubal intraepithelial carcinoma.
    Howitt BE; Hanamornroongruang S; Lin DI; Conner JE; Schulte S; Horowitz N; Crum CP; Meserve EE
    Am J Surg Pathol; 2015 Mar; 39(3):287-93. PubMed ID: 25581732
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A cautious view of putative precursors of serous carcinomas in the fallopian tubes of BRCA mutation carriers.
    Cass I; Walts AE; Barbuto D; Lester J; Karlan B
    Gynecol Oncol; 2014 Sep; 134(3):492-7. PubMed ID: 25026639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective study of a 16 year cohort of BRCA1 and BRCA2 carriers presenting for RRSO: Prevalence of invasive and in-situ carcinoma, with follow-up.
    Blok F; Dasgupta S; Dinjens WNM; Roes EM; van Beekhuizen HJ; Ewing-Graham PC
    Gynecol Oncol; 2019 May; 153(2):326-334. PubMed ID: 30894273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis.
    Bijron JG; Seldenrijk CA; Zweemer RP; Lange JG; Verheijen RH; van Diest PJ
    Am J Surg Pathol; 2013 Aug; 37(8):1123-30. PubMed ID: 23648462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high-grade serous carcinomas.
    Soong TR; Howitt BE; Miron A; Horowitz NS; Campbell F; Feltmate CM; Muto MG; Berkowitz RS; Nucci MR; Xian W; Crum CP
    J Pathol; 2018 Nov; 246(3):344-351. PubMed ID: 30043522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serous tubal intraepithelial carcinoma (STIC) - clinical impact and management.
    Weinberger V; Bednarikova M; Cibula D; Zikan M
    Expert Rev Anticancer Ther; 2016 Dec; 16(12):1311-1321. PubMed ID: 27732120
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
    Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
    Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
    Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
    Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Incidental Serous Tubal Intraepithelial Carcinoma that Developed into Primary Peritoneal Serous Carcinoma in a Patient without BRCA Mutation.
    Chong GO; Park JY; Lee HJ
    Am J Case Rep; 2020 Feb; 21():e921146. PubMed ID: 32034117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO).
    Stanciu PI; Ind TEJ; Barton DPJ; Butler JB; Vroobel KM; Attygalle AD; Nobbenhuis MAE
    J Ovarian Res; 2019 May; 12(1):50. PubMed ID: 31128592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early detection of high-grade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery.
    Rabban JT; Garg K; Crawford B; Chen LM; Zaloudek CJ
    Am J Surg Pathol; 2014 Jun; 38(6):729-42. PubMed ID: 24820399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next-Generation Sequencing of Tubal Intraepithelial Carcinomas.
    McDaniel AS; Stall JN; Hovelson DH; Cani AK; Liu CJ; Tomlins SA; Cho KR
    JAMA Oncol; 2015 Nov; 1(8):1128-32. PubMed ID: 26181193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of occult ovarian cancer in the series of 155 consequently operated high risk asymptomatic patients - Slovenian population based study.
    Gornjec A; Merlo S; Novakovic S; Stegel V; Gazic B; Perhavec A; Blatnik A; Krajc M
    Radiol Oncol; 2020 May; 54(2):180-186. PubMed ID: 32463390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up.
    Olivier RI; van Beurden M; Lubsen MA; Rookus MA; Mooij TM; van de Vijver MJ; van't Veer LJ
    Br J Cancer; 2004 Apr; 90(8):1492-7. PubMed ID: 15083174
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status.
    Manchanda R; Abdelraheim A; Johnson M; Rosenthal AN; Benjamin E; Brunell C; Burnell M; Side L; Gessler S; Saridogan E; Oram D; Jacobs I; Menon U
    BJOG; 2011 Jun; 118(7):814-24. PubMed ID: 21392246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.